MedKoo Cat#: 577737 | Name: Cudetaxestat

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cudetaxestat is a non-competitive autotaxin inhibitor under investigation for its potential in treating fibrotic diseases. In vitro studies have demonstrated that cudetaxestat effectively inhibits autotaxin enzymatic activity with nanomolar potency, reducing the production of lysophosphatidic acid (LPA), a key mediator of fibrosis and inflammation. Compared to earlier autotaxin inhibitors, cudetaxestat exhibits a prolonged inhibitory effect due to its covalent binding mechanism. Cellular assays further confirm its ability to suppress LPA-driven signaling pathways, leading to reduced fibroblast proliferation and extracellular matrix deposition. These findings suggest cudetaxestat as a promising antifibrotic agent with superior pharmacological properties.

Chemical Structure

Cudetaxestat
Cudetaxestat
CAS#1782070-21-6 (free base)

Theoretical Analysis

MedKoo Cat#: 577737

Name: Cudetaxestat

CAS#: 1782070-21-6 (free base)

Chemical Formula: C21H15Cl2F2N3O2S

Exact Mass: 481.0230

Molecular Weight: 482.33

Elemental Analysis: C, 52.29; H, 3.13; Cl, 14.70; F, 7.88; N, 8.71; O, 6.63; S, 6.65

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Synonym
Cudetaxestat; PAT-409; PAT-409; PAT 409; PAT409; BLD-0409; BLD 0409; BLD0409;
IUPAC/Chemical Name
3-{[2,6-dichloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl]sulfanyl}-2-fluorobenzoic acid
InChi Key
NMDFAQXLJQRHMS-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H15Cl2F2N3O2S/c1-2-8-27-10-11(9-26-27)28-18-13(6-7-14(22)17(18)25)19(20(28)23)31-15-5-3-4-12(16(15)24)21(29)30/h3-7,9-10H,2,8H2,1H3,(H,29,30)
SMILES Code
O=C(O)C1=CC=CC(SC2=C(Cl)N(C3=CN(CCC)N=C3)C4=C2C=CC(Cl)=C4F)=C1F
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 482.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1. Jia Y, Li Y, Xu XD, Tian Y, Shang H. Design and Development of Autotaxin Inhibitors. Pharmaceuticals (Basel). 2021 Nov 22;14(11):1203. doi: 10.3390/ph14111203. PMID: 34832985; PMCID: PMC8622848. 2. Tan Z, Lei H, Guo M, Chen Y, Zhai X. An updated patent review of autotaxin inhibitors (2017-present). Expert Opin Ther Pat. 2021 May;31(5):421-434. doi: 10.1080/13543776.2021.1867106. Epub 2021 Jan 12. PMID: 33342311.